We believe Medicare fraud is an epidemic nationwide, and off-labeled pharmaceutical products is just the tip of the iceburg.
(PRWEB) August 07, 2014
The Corporate Whistleblower Center is urging physicians or healthcare industry insiders to call them at 866-714-6466 if they have well documented proof a pharmaceutical company is deeply involved in the promotion of an off-labeled drug. The reward for this type of information can be significant.
As a recent example, in April 2014, the Justice Department announced a pharmaceutical company named Astellas Pharma US Inc. will pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use.
The settlement resolves allegations that, between 2005 and 2010, Astellas allegedly marketed and promoted the sale of Mycamine for pediatric use, which was not a medically accepted indication and, therefore, not covered by federal health care programs. During this time frame, the FDA approved Mycamine to treat adult patients suffering from serious and invasive infections caused by the fungus Candida, including infections in the esophagus, the blood and the abdomen, and to prevent Candida infections in adults undergoing stem cell transplants. From 2005 through June 2013, however, Mycamine was not approved to treat pediatric patients for any use.
The whistleblower in the Astellas settlement will receive $708,852 in compensation.
The Corporate Whistleblower Center says, “Well documented information concerning off-labeled pharmaceutical products, or other schemes that could result in the defrauding of Medicare, such as being overbilled, for example, can lead to significant rewards for the whistleblower. We believe Medicare fraud is an epidemic nationwide, and off-labeled pharmaceutical products is just the tip of the iceburg. It doesn't matter if a whistleblower is in Miami, Los Angeles, New York, Pittsburgh, Boston, Houston, Minneapolis, Las Vegas, Seattle, or Saint Louis. So long as they have information about off-labeled drugs, or other schemes that could lead to Medicare fraud, we want the whistleblower to call us at 866-714-6466, so we can explain whistleblower reward programs to them.” http://CorporateWhistleblowerCenter.Com
Simple rules for a whistleblower from the Corporate Whistleblower Center:
- Do not go to the government first if you are a major whistleblower. The Corporate Whistleblower Center says, "Major whistleblowers frequently go to the federal government thinking they will help. It's a huge mistake. Frequently government officials could care less, or they are incompetent."
- Do not go to the news media with your whistleblower information. Public revelation of a whistleblower's information could destroy any prospect for a reward.
- Do not try to force a government contractor, or corporation to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, "Fraud is so rampant among federal contractors, that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. We say, come to us first, tell us what type of information you have, and if we think its sufficient, we will help find the right law firms, to assist in advancing your information."
- The Corporate Whistleblower Center wants to emphasize there are high quality whistleblowers in every state including California, New York, Florida, Texas, Massachusetts, Maryland, Virginia, Ohio, Pennsylvania, North Carolina, Georgia, Alabama, Mississippi, Louisiana, Oklahoma, Missouri, Michigan, Indiana, Illinois, Wisconsin, Minnesota, Nebraska, Kansas, Colorado, Utah, New Mexico, Arizona, Nevada, Oregon, Washington, and Alaska.
Any type of insider, or employee, who possesses significant proof of their employer, or a government contractor fleecing the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466, or they can contact the group via their web site at http://CorporateWhistleBlowerCenter.Com.
For attribution purposes please refer to the April 2014 United States Department of Justice press release. http://www.justice.gov/opa/pr/2014/April/14-civ-391.html
The lawsuit is captioned United States ex rel. Smith v. Astellas Pharma, US Inc. et al., No. 10-999 (E.D. Pa.).